Navigation Links
Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool

Noblis, Inc., a leading provider of science, technology, and strategy services to the federal government, announced in a paper published this week in the scientific journal Viruses (, that government and Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to detect the Ebola virus. Noblis worked with the Department of Defense’s Medical Countermeasure Systems (MCS), a component of the Joint Program Executive Office for Chemical and Biological Defense and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

The ongoing challenge to medical personnel in the field is to identify the Ebola virus as it continues, as does any virus, to evolve and change genomically. Using a whole genome approach and a novel algorithm called BioVelocity—developed by Noblis to run on supercomputers at their Danville, Virginia, Center for Applied High Performance Computing—the scientific collaborators identified ten new genomic signatures of the Ebola virus that were not found using current technology and identification techniques.

“Viruses evolve temporally and regionally,” noted Noblis scientist Walter Berger, “and there is evidence that the current Ebola virus is mutating more than expected. The diagnostics now in use have not been tested against sequences from these new variants and may not target the genetic regions that detect all the variants. Updates to genomic detection methods require that assays be developed and validated; most importantly, the optimal genomic regions for detection need to be identified. BioVelocity exploits the massive amounts of data generated by DNA sequencers to identify genomic regions that are conserved even when genetic variations occur and that are also signatures unique for that organism when compared to all other genomes of all other species—faster, more completely, and more accurately.”

“In high consequence outbreaks, it is critically important to assess how well current identification techniques perform against the species circulating in the outbreak. Whole genome sequencing of the circulating species—together with tools such as BioVelocity—can have a material impact on the spread of the disease, and on lives,” stated Dr. Shanmuga Sozhamannan of the Tauri Group, who supports MCS’ Critical Reagents Program (CRP) which develops and validates detection assays.

“Collecting and analyzing enough strains of these re-emerging pathogens enhances our understanding of the organism’s population dynamics,” states Dr. Michael A. Smith, Director of the CRP. “Programs such as CRP’s Targeted Acquisition of Reference Materials Augmenting Capabilities (TARMAC), collect the strains, and BioVelocity provides fast and complete analysis of the genomes needed. The diagnostics and medical countermeasures we develop are only as good as the data we have.”

Noblis is currently working to make BioVelocity available to other researchers and, more importantly, to support field personnel fighting the West Africa Ebola outbreak.

About BioVelocity
Noblis invented BioVelocity for clinicians, practitioners, and researchers in healthcare, pharmaceutical, government, and academic organizations that are practicing personalized medicine, developing genomic-based drugs, and performing longitudinal studies. Noblis’ BioVelocity is a bioinformatics platform including high performance computing infrastructure, our innovative algorithm, and our approach to genomic reference indices. It has demonstrated dramatic improvements in performance over current technologies. At speeds 50x faster than industry standard, BioVelocity delivers increased functionality, increased throughput, and improved accuracy—all at a lower cost. Through the ability to generate exhaustive alignments for all input reads against multiple reference genomes in one run, BioVelocity is very powerful for genomics solutions ranging from metagenomics and genomic analysis of pathogens, to human disease discovery research and personalized medicine. BioVelocity will enable realization of personalized medicine and will reduce the time (by weeks and months) for diagnostics and treatments, reduce the time to market (by months and even years) for new drugs, and allow medical practitioners to spend more time focusing on patient solutions.

About Noblis    
Noblis, Inc. is a nonprofit science, technology, and strategy organization that brings the best of scientific thought, management, and engineering expertise in an environment of independence and objectivity. We work with a wide range of government and industry clients in the areas of national security, intelligence, transportation, healthcare, environmental sustainability, and enterprise engineering. Together with our wholly owned subsidiaries, Noblis ESI and Noblis NSP, we tackle the nation’s toughest problems and support our clients’ most critical missions.

About Medical Countermeasure Systems
The U.S. Department of Defense’s Joint Project Manager Medical Countermeasure Systems (JPM-MCS) is one of seven JPMs within the Joint Program Executive Office for Chemical and Biological Defense. JPM-MCS facilitates the advanced development and acquisition of medical countermeasures and systems to enhance our nation’s biodefense response capability. MCS’ CRP serves as the principal source of high-quality, validated and standardized biological detection assays and reagents.

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
2. Israel’s BioEnergy Leaders Meet for Two Days of Deliberations with U.S. Government Counterparts - Following Wednesday White House Briefing
3. iBio Pharmaceutical Technology Embraced by the Government of Brazil
4. Hands-on Healthcare Simulations in Government, New Webinar Hosted by Xtalks
5. Adheris Inc. Files For Preliminary Injunction To Stop U.S. Government From Infringing On Constitutionally Protected Speech
6. Day Two of AdvaMed 2013 to Feature Government and Industry Leaders on MedTech Challenges and Opportunities
7. Government Steps Up Awareness for Obstructive Sleep Apnea in America’s Workforce
8. The Employment Report for October, 2013: Economy Continues to Grow Despite Government Shut-down
9. Dr. Rongxiang Xu Receives the Prestigious Scroll Award from Los Angeles County Government
10. NEOMED Receives $12 Million from Federal Government
11. Korean Government Program Supports Vegalabs Research and Development
Post Your Comments:
(Date:11/29/2018)... , ... November 29, 2018 , ... RAGS, today announced ... by Kickstart Seed Fund, with participation from existing investor and board member Jeremy Andrus, ... Smith of Cotopaxi. The additional funding will enable the company to accelerate its growth ...
(Date:11/20/2018)... ... 2018 , ... Patients with missing teeth in Sandy Springs, GA, Alpharetta, GA, ... Myers at THE DENTIST Centers without a referral. Dr. Myers is a skilled cosmetic ... years. He now offers skilled dental care in two practice locations THE DENTIST Windward ...
(Date:11/13/2018)... ... November 12, 2018 , ... AseptiScope(TM), Inc. announces ... large U.S. studies, published last week, confirm pose a significant health risk. ... (AJIC) conclude that stethoscopes are often improperly or rarely disinfected. In the AJIC ...
(Date:11/11/2018)... ... ... Triple W, an innovator of connected health devices, today announced that it has ... the first health tech wearable device for incontinence that monitors how full your bladder ... was made during CES Unveiled New York, an invite-only tech event bringing together top ...
Breaking Biology Technology:
(Date:12/5/2018)... ... 2018 , ... The new program allows 3rd ... innovative solutions for which high-speed imaging is a necessary albeit challenging component. , ... and instrumentation, allowing partner companies to dedicate their resources on their core strengths ...
(Date:11/29/2018)... KING OF PRUSSIA, Pa. (PRWEB) , ... November ... ... completed an equity investment in Semba Biosciences with the intention of acquiring full ... and an Equity Participation Agreement was executed on November 14, 2018. “We are ...
(Date:11/27/2018)... ... November 26, 2018 , ... uBiome, the ... of the website IBDwatch and Gastroenterology Fellow at the University of Louisville, to ... around the world, Dr. Wuerth will bring to uBiome knowledge and research on ...
Breaking Biology News(10 mins):